Mohammed Gbadamosi

Mohammed Gbadamosi, Ph.D.

Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Email: mgbadamosi@ufl.edu

About Mohammed Gbadamosi

Dr. Mohammed Gbadamosi is an Assistant Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy.

Dr. Gbadamosi completed his graduate studies Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy. Thereafter, He completed his postdoctoral training as an NIH T32 Postdoctoral Fellow in the Program for Applied Research and Development in Genomic Medicine (PARADIGM) at the University of Florida College of Pharmacy under the mentorship of Dr. Duane Mitchell.

In 2023, Dr. Gbadamosi was selected as one of thirteen individuals to receive the highly prestigious NIH Director’s Early Independence Award. This award enables outstanding junior scientists with the intellect, scientific creativity, drive, and maturity to bypass the traditional postdoctoral training period and launch independent research careers. Dr. Gbadamosi leads a collaborative multidisciplinary research group and his research broadly leverages advanced molecular, cellular, and computational approaches to optimize the efficacy of chemotherapeutic and immuno-oncology agents. His research spans basic and translational sciences with the ultimate end goal of maximizing the efficacy of combinatorial strategies using chemotherapy and immunotherapy (chemoimmunotherapy) and developing curative chemoimmunotherapeutic treatment regimens.

Dr. Gbadamosi’s Early Independence Award study focuses on utilizing multi-omics and machine learning approaches to (1) identify, characterize, and establish the clinical relevance of molecular features that influence chemoimmunomodulation in metastatic triple-negative breast cancer and other types of cancers and (2) construct computational models capable of predicting chemoimmunomodulatory effects using a patient’s baseline molecular profile thus enabling refined methods for personalizing chemoimmunotherapy. Given the poor prognosis and critical health disparities observed in triple-negative breast cancer and the poor efficacy observed from chemoimmunotherapy in triple-negative breast cancer, this study is of critical importance and holds the potential to drastically improve clinical outcomes.

Dr. Gbadamosi also holds membership in the University of Florida Brain Tumor Immunotherapy Program and Preston A. Wells, Jr. Center for Brain Tumor Therapy where he leads studies focused on developing and characterizing models of triple-negative breast cancer brain metastases and their response to chemoimmunotherapy.

Dr. Gbadamosi’s leadership at the University of Florida has driven transformative initiatives, effecting policy changes and fostering academic excellence. His notable contributions include founding the College of Pharmacy Graduate Student Organization, initiating the UF Graduate Education Diversity Champion Award, and serving on the College of Pharmacy Dean’s Leadership Council (2020-2023). Dr. Gbadamosi has a passion for serving the next generation of trainees and students as a mentor, providing advocacy, opportunities, and experiences that enable them to succeed. Thus far he has mentored 6 trainees (4 undergraduate and 2 PharmD students) and actively engages with mentorship-focused programs such as the Maximizing Access to Research Careers (MARC) program. Dr. Gbadamosi serves on the Gene Regulation in Cancer NIH Study Section, is a Fellow of the Cancer Research Education and Engagement (CaRE2) Health Equity Center, and contributes as a reviewer for esteemed journals. His scientific contributions are reflected in five research articles, one patent, and numerous award-winning presentations.

Related Links:

Accomplishments

NIH Director's Early Independence Award
2023 · NIH Office of the Director
NIH T32 PARADIGM Postdoctoral Fellowship
2022 · NHGRI/NIH
Predoctoral Fellowship
2019 · American Foundation for Pharmaceutical Education
SECU MD Foundation Scholarship
2019 · State Employees Credit Union of Maryland

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-2751-1172

Publications

2024
DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group
Clinical Cancer Research. OF1-OF9 [DOI] 10.1158/1078-0432.ccr-23-2073.
2023
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Blood advances. 7(9):1769-1783 [DOI] 10.1182/bloodadvances.2022007934. [PMID] 36111891.
2022
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Leukemia. 36(8):2022-2031 [DOI] 10.1038/s41375-022-01622-0. [PMID] 35688939.
2021
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future oncology (London, England). 17(3):263-277 [DOI] 10.2217/fon-2020-0746. [PMID] 33356566.
2019
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Leukemia & lymphoma. 60(9):2287-2290 [DOI] 10.1080/10428194.2019.1569232. [PMID] 30721105.
2018
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Future oncology (London, England). 14(30):3199-3213 [DOI] 10.2217/fon-2018-0325. [PMID] 30039981.

Grants

Sep 2023 ACTIVE
Decoding the Heterogeneity in Chemo-Immunomodulation to Unlock the Potential of Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer
Role: Principal Investigator
Funding: NATL INST OF HLTH OD
Sep 2020 – Aug 2021
Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment Strategies
Role: Principal Investigator
Funding: AMER FOU FOR PHARM EDU

Education

Ph.D.
2021 · University of Florida College of Pharmacy
B.S.
2017 · University of Delaware
A.S.
2013-2015 · Harford Community College

Contact Details

Emails:
Business:
mgbadamosi@ufl.edu
Addresses:
Business Mailing:
PO Box 100486
GAINESVILLE FL 32610
Business Street:
1345 CENTER DR RM PG 22
GAINESVILLE FL 32610